Target intelligence / Profile preview

Mucin glycoproteins (MUC) (MUC)

Target
MUC
Molecular classification
Glycoprotein, Secreted protein, Extracellular matrix protein
01

Overview

Mucin glycoproteins are high-molecular-weight, heavily O-glycosylated proteins that constitute the primary structural framework of the respiratory mucus gel (Source: PMC6529204). In the human airways, the two dominant gel-forming mucins are MUC5AC, primarily secreted by surface goblet cells, and MUC5B, produced by both goblet cells and submucosal glands (Source: UniProt P35226, Q9HC84). These proteins play a critical role in the innate immune system by trapping inhaled pathogens and debris, which are subsequently cleared from the lungs via the mucociliary escalator (Source: PubMed 29030118). However, in pathological conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and cystic fibrosis, mucin hypersecretion and altered glycosylation lead to increased mucus viscosity and airway obstruction (Source: StatPearls NBK538311). Pharmacological intervention typically involves mucolytic agents like N-acetylcysteine, which reduce mucus elasticity by cleaving disulfide bonds between mucin monomers, or mucokinetics that enhance clearance (Source: PubChem CID 12035). Understanding the balance between MUC5AC and MUC5B is increasingly recognized as vital for developing targeted therapies for chronic lung diseases.

Other names
Airway mucinsGel-forming mucinsTracheobronchial mucinsMUC5ACMUC5BAirway secretions
02

Mechanism of action

Mucolytic agents (e.g., N-acetylcysteine) reduce mucus viscosity by cleaving the disulfide bonds that cross-link mucin polymers, while mucoregulators (e.g., carbocisteine) influence the production and secretion of mucins from goblet cells, and mucokinetics (e.g., guaifenesin) enhance the effectiveness of cough or ciliary transport (Source: PubMed 24841175, StatPearls NBK538311).

03

Biological functions

Mucociliary clearanceInnate immune defenseEpithelial protectionHydrationLubrication
04

Disease associations

Chronic Obstructive Pulmonary Disease (COPD)AsthmaCystic FibrosisBronchiectasisRespiratory tract infection
05

Safety considerations

Bronchospasm (particularly with inhaled mucolytics)Gastrointestinal irritationAirway obstruction due to rapid liquefaction of secretionsInhibition of the natural protective mucosal barrier
06

Interacting drugs

N-acetylcysteine

6 more in the full profile.

07

Biomarkers

MUC5AC protein levelsMUC5B protein levelsSputum viscosityMucus solids concentrationMUC5AC/MUC5B ratio

Beyond the preview

Go deeper on Mucin glycoproteins (MUC) (MUC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin glycoproteins (MUC) (MUC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call